Market revenue in 2024 | USD 631.4 million |
Market revenue in 2030 | USD 986.0 million |
Growth rate | 7.7% (CAGR from 2024 to 2030) |
Largest segment | Defibrillators |
Fastest growing segment | Defibrillators |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) |
Key market players worldwide | Stryker Corp, BIOTRONIK, SCHILLER, Medtronic PLC, Abbott Laboratories, Koninklijke Philips NV, ZOLL Medical Corporation, Boston Scientific Corp, LivaNova PLC, Progetti Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac rhythm management devices market will help companies and investors design strategic landscapes.
Defibrillators was the largest segment with a revenue share of 50.63% in 2024. Horizon Databook has segmented the China cardiac rhythm management devices market based on pacemakers, defibrillators, cardiac resynchronization therapy (crt) covering the revenue growth of each sub-segment from 2018 to 2030.
Collaborations between domestic Chinese companies and international medical device manufacturers facilitate technology transfer and knowledge exchange. International companies bring advanced technologies and expertise in CRM device development, while local companies provide insights into the specific needs & preferences of the Chinese market.
For instance, in August 2021, Life Tech Scientific Corporation, a Chinese medical device company, expanded its partnerships with Medtronic to advance strategic cooperation on the Heart Tone domestic pacemaker initiative and initiate collaboration on domestically produced MRI-compatible pacemakers.
The government in China has taken initiatives to increase the production of medical devices within the country. According to an article published in 2022, the Volume-based Procurement (VBP) Act was announced in 2020. This act focuses on the VBP of high-value medical supplies to address the rising costs of such products.
Horizon Databook provides a detailed overview of country-level data and insights on the China cardiac rhythm management devices market, including forecasts for subscribers. This country databook contains high-level insights into China cardiac rhythm management devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account